Sleep deprivation can lead the brain to produce more of the Alzheimer’s-linked protein amyloid beta than the its waste-disposal system can handle, according to a small study.
“Understanding how lack of sleep relates to the concentrations of amyloid beta in the brain will help direct future research into therapeutics…”
Levels of the protein rise, potentially setting off a sequence of changes to the brain that can end with dementia.
“This study is the clearest demonstration in humans that sleep disruption leads to an increased risk of Alzheimer’s disease through an amyloid beta mechanism,” says senior author Randall Bateman, professor of neurology at Washington University in St. Louis. “The study showed that it was due to overproduction of amyloid beta during sleep deprivation.”
More than 5 million Americans live with Alzheimer’s, a disease characterized by gradual memory loss and cognitive decline.
Rising amyloid beta levels
David Holtzman, a professor of neurology, and Yo-El Ju, an assistant professor of neurology, have shown that sleeping poorly increases levels of brain proteins such as amyloid beta that are linked to Alzheimer’s disease. But it wasn’t clear why amyloid beta levels rise in a tired brain.
Bateman, first author Brendan Lucey, an assistant professor of neurology, and colleagues studied eight people ages 30 to 60 with no sleep or cognitive problems. Researchers assigned the participants randomly to one of three scenarios: having a normal night’s sleep without any sleep aids; staying up all night; or sleeping after treatment with sodium oxybate, a prescription medication for sleep disorders. Sodium oxybate increases slow-wave sleep—the deep, dreamless phase of sleep that people need to wake up feeling refreshed.
“I don’t want anyone to think that they are going to get Alzheimer’s disease because they pulled an all-nighter in college…”
Each scenario occurred during 36 hours of monitoring, starting in the morning and continuing through the afternoon of the following day. The researchers took samples of the fluid that surrounds the brain and spinal cord every two hours to monitor how amyloid beta levels change with time of day and tiredness.
All eight participants returned four to six months later to undertake a second scenario, and four people completed all three. Studying the same people under different conditions provides the statistical power to detect changes in amyloid beta levels.
Amyloid beta levels in sleep-deprived people were 25 to 30 percent higher than in those who had slept the night through. After a sleepless night, amyloid beta levels were on par with the levels seen in people genetically predisposed to develop Alzheimer’s at a young age.
“I don’t want anyone to think that they are going to get Alzheimer’s disease because they pulled an all-nighter in college,” Lucey says. “One night probably has no effect on your overall risk of Alzheimer’s. We are really much more concerned about people with chronic sleep problems.”
An estimated 50 million to 70 million American adults struggle to get a good night’s sleep. Some have medical conditions such as sleep apnea or restless leg syndrome that interfere with their rest. But others are simply trying to pack too much into a day.
When amyloid beta levels in the brain are persistently high, the protein is more likely to start collecting into plaques. Such plaques damage nearby neurons and can trigger a cascade of destructive brain changes. These plaques dot the brains of the brains of people with Alzheimer’s.
Amyloid beta is a byproduct of normal brain activity. The researchers found that when people stay awake, their brains continue to produce amyloid beta through the night. A sleeping brain produces much less. Asleep or awake, however, the brain clears the protein away at the same rate, so the increased production during sleep deprivation leads to higher levels of the damaging protein.
“Understanding how lack of sleep relates to the concentrations of amyloid beta in the brain will help direct future research into therapeutics,” Lucey says. “This information could help us figure out how to reduce amyloid beta deposition over time in people whose sleep is chronically disrupted.”
In the study, people who took sleep medication had levels of amyloid beta no lower than people who had slept normally.
“We were looking at healthy, well-rested adults,” Lucey says. “This suggests that if you already are getting enough sleep, getting more sleep with the help of medication may not provide any benefit.”
Further studies are needed to determine whether improving sleep in people with sleep problems can reduce amyloid beta levels and risk of Alzheimer’s disease, the researchers say.
The researchers report their findings in Annals of Neurology.
Support for this research came from the National Institutes of Health (NIH); McDonnell Center for Systems Neuroscience; MetLife Foundation Award for Medical Research; and Cambridge Isotope Laboratories.